Detalhe da pesquisa
1.
Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort.
Blood
; 139(22): 3278-3289, 2022 06 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-35196370
2.
Identifying and addressing unmet clinical needs on the use of zanubrutinib in chronic lymphocytic leukemia: A consensus-based position paper from an ad hoc expert panel.
Hematol Oncol
; 42(2): e3255, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38362952
3.
Ibrutinib as first line therapy in chronic lymphocytic leukemia patients over 80 years old: A retrospective real-life multicenter Italian cohort.
Hematol Oncol
; 42(1): e3249, 2024 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-38287529
4.
Preexisting and treatment-emergent autoimmune cytopenias in patients with CLL treated with targeted drugs.
Blood
; 137(25): 3507-3517, 2021 06 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-33651883
5.
Unmet clinical needs in the use of zanubrutinib in malignant lymphomas (Waldenström macroglobulinemia, marginal zone lymphoma and mantle cell lymphoma): A consensus-based position paper from an ad hoc expert panel.
Hematol Oncol
; 41(5): 795-808, 2023 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-37165730
6.
Many People With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Benefit From Ibrutinib Treatment Up To 8 Years: A Plain Language Summary.
Future Oncol
; 2023 01 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-36617990
7.
Plain Language Summary of the iNNOVATE study: ibrutinib plus rituximab is well-tolerated and effective in people with Waldenström's macroglobulinemia.
Future Oncol
; 19(5): 345-353, 2023 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-36815271
8.
Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial.
Lancet Oncol
; 23(8): 1031-1043, 2022 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35810754
9.
Zanubrutinib for the treatment of patients with Waldenström macroglobulinemia: 3 years of follow-up.
Blood
; 136(18): 2027-2037, 2020 10 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-32698195
10.
A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study.
Blood
; 136(18): 2038-2050, 2020 10 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-32731259
11.
First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab: final analysis of the randomized, phase III iLLUMINATE trial.
Haematologica
; 107(9): 2108-2120, 2022 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35021599
12.
Use of BTK inhibitors with special focus on ibrutinib in Waldenström macroglobulinemia: An expert panel opinion statement.
Hematol Oncol
; 40(3): 332-340, 2022 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-35212014
13.
Use of BTK inhibitors with focus on ibrutinib in mantle cell lymphoma: An expert panel opinion statement.
Hematol Oncol
; 40(4): 518-527, 2022 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-35247223
14.
Phase 3 Trial of Ibrutinib plus Rituximab in Waldenström's Macroglobulinemia.
N Engl J Med
; 378(25): 2399-2410, 2018 Jun 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-29856685
15.
Ibrutinib for the treatment of Bing-Neel syndrome: a multicenter study.
Blood
; 133(4): 299-305, 2019 01 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-30523119
16.
Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL.
Blood
; 134(11): 851-859, 2019 09 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-31340982
17.
Early progression as a predictor of survival in marginal zone lymphomas: an analysis from the FIL-NF10 study.
Blood
; 134(10): 798-801, 2019 09 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-31292118
18.
Dual cytoplasmic and nuclear localization of HTLV-1-encoded HBZ protein is a unique feature of adult T-cell leukemia.
Haematologica
; 106(8): 2076-2085, 2021 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33626865
19.
A multicenter total therapy strategy for de novo adult Philadelphia chromosome positive acute lymphoblastic leukemia patients: final results of the GIMEMA LAL1509 protocol.
Haematologica
; 106(7): 1828-1838, 2021 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33538150
20.
Pretreatment with ibrutinib reduces cytokine secretion and limits the risk of obinutuzumab-induced infusion-related reactions in patients with CLL: analysis from the iLLUMINATE study.
Ann Hematol
; 100(7): 1733-1742, 2021 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-34018029